(5β,17xi)-胆-3-烯-24-酸 | 73677-19-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 中文名称: (5β,17xi)-胆-3-烯-24-酸
• 中文别名: 2-氯-5-(1-羟基-3-氧代-2H-异吲哚-1-基)苯磺酰胺;2-[4-[2-羟基-3-(丙-2-基氨基)丙氧基]苯基]乙酰胺
• 英文名称: Atenolol and chlorthalidone
• 英文别名: 2-chloro-5-(1-hydroxy-3-oxo-2H-isoindol-1-yl)benzenesulfonamide;2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide
• CAS: 73677-19-7
• 化学式: C28H33ClN4O7S
• 分子量: 605.1
• InChiKey: GEGCOFDJWXJACT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.38
• 重原子数：
  41
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  202
• 氢给体数：
  6
• 氢受体数：
  9

文献信息

• EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND BETA-ADRENERGIC ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE
  申请人：Pharmacia Corporation

  公开号：EP1303306B1

  公开（公告）日：2006-06-21
• Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
  申请人：Alexander C. John

  公开号：US20050215537A1

  公开（公告）日：2005-09-29

  A combination therapy comprising a therapeutically-effective amount of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amount of a beta-adrenergic antagonist is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred beta-adrenergic antagonists are those compounds having high potency and bioavailability. Preferred epoxy-steroidal aldosterone receptor antagonists are 20-spiroxane steroidal compounds characterized by the presence of a 9α,11α-substituted epoxy moiety. A preferred combination therapy includes the beta-adrenergic antagonist metoprolol ((±)1-(isopropylamino)-3-[p-(2-methoxyethyl)phenoxyl]-2-propanolol succinate) and the aldosterone receptor antagonist epoxymexrenone.
• METHOD AND APPARATUS FOR PACKAGING AND DISPENSING PHARMACEUTICALS
  申请人：Tramonte Arturo

  公开号：US20110240504A1

  公开（公告）日：2011-10-06

  A method of packaging one or more pharmaceuticals comprising separating a plurality of unit doses into a plurality of unit dose compartments, wherein each unit dose compartment of the plurality of unit dose compartments holds only one unit dose of the plurality of unit doses, each unit dose having the same strength, wherein the plurality of unit doses is precisely a quantity equal to a most commonly prescribed number of unit doses in individual prescriptions for the unit dose, or a multiple thereof is provided. Also provided are kits prepared by the method. Methods for designing such kits and packaging are also provided.
• Methods for Predicting Patient Response to DMARDs
  申请人：Queen Mary University of London

  公开号：US20220349886A1

  公开（公告）日：2022-11-03

  The present invention provides a method for predicting whether a patient having, suspected of having, or at risk of developing an inflammatory condition will respond to treatment with a disease-modifying antirheumatic drug (DMARD) comprising measuring the level of at least one specialized pro-resolving mediator (SPM) in a DMARD naïve patient sample and classifying the patient as a predicted DMARD responder or a predicted DMARD non-responder. The present invention also provides a method of assessing the efficacy of a disease-modifying antirheumatic drug (DMARD) for use in the treatment of an inflammatory condition in a patient. The present invention also provides a method of predicting which rheumatoid arthritis pathotype a patient having, suspected of having, or at risk of developing rheumatoid arthritis will develop.
• US7790905B2
  申请人：——

  公开号：US7790905B2

  公开（公告）日：2010-09-07